US20080166787A1 - T Cell Apoptosis Inducer - Google Patents
T Cell Apoptosis Inducer Download PDFInfo
- Publication number
- US20080166787A1 US20080166787A1 US11/883,377 US88337706A US2008166787A1 US 20080166787 A1 US20080166787 A1 US 20080166787A1 US 88337706 A US88337706 A US 88337706A US 2008166787 A1 US2008166787 A1 US 2008166787A1
- Authority
- US
- United States
- Prior art keywords
- lactic acid
- cells
- ferm
- cell apoptosis
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/115—Amylovorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Definitions
- the present invention relates to an inducer of apoptosis of T cells, which comprises a lactic acid bacterial cell as an active component.
- the mammalian immune system protects the host by recognizing bacteria, viruses and kinds of stuff as antigens and eliminating them through the action of the system.
- the immune system is roughly classified into cellular immunity and humoral immunity, and the both immune systems affect each other to optimize the immune reactions for host defense.
- T cells participate to play an important role in the modulation of the function of the immune system.
- Th1 cells are broadly classified into Th1 and Th2 cells.
- Th1 cells enhance cellular immunity and Th2 cells enforce humoral immunity.
- the imbalance in the Th1/Th2 ratio may cause various immune diseases. It is considered that when Th1 cells are dominant, an organ-specific autoimmune disease occurs and when Th2 cells are dominant, a type I allergy or related diseases occur. Therefore, there has been a requirement for a food, a food additive and a medicine, which are useful for realizing the potential for maintaining the Th1/Th2 balance.
- references cited herein include Ina K. et al., J. Immunol. 163: 1081, 1999, Boirivant M. et al., Gastroenterology 116: 557, 1999, Watanabe-Fukunaga R. et al., Nature 356:314, 1992, Akdis M. et al., FASEB J. 17: 1026, 2003 and Guerra F. et al., J. Allergy Clin. Immunol. 107:647, 2001.
- An object of the present invention is to provide a novel and safe means for inducing apoptosis of excess T cells that may cause various diseases and to facilitate the prevention and cure of a disease such as an organ-specific autoimmune disease or a type I allergy.
- the present invention is based on a new finding that when bacterial cells of a specific type of lactic acid bacterial strain is introduced into a state of excess reactivity of T cells, apoptosis of T cells is induced.
- the present invention provides an inducer of T cell apoptosis comprising as an active ingredient a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium . Furthermore, the present invention provides a health food for inducing T cell apoptosis comprising a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium.
- the present invention provides novel lactic acid bacteria, i.e., Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531).
- novel lactic acid bacteria i.e., Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531).
- the inducer of T cell apoptosis according to the present invention is safe even if it is orally taken for a long period of time, because of long experience of usage of lactic acid bacteria as starter cultures for fermentation foods such as yoghurt, pickles and the kind of stuff.
- the inducer of the invention induces apoptosis of excess T cells to prevent and/or cure an inflammatory disease, such as an organ-specific autoimmune disease or an allergy caused by excess T cells.
- FIG. 1 shows induction of naive T cell apoptosis by a variety of lactic acid bacteria.
- FIG. 2 shows a dose-dependent induction of T cell apoptosis by Lactobacillus acidophilus L-92.
- FIG. 3 shows induction of Th2 cell apoptosis by a variety of lactic acid bacteria.
- FIG. 4 shows level of IL-4 produced by Th2 cells treated with a variety of lactic acid bacteria.
- FIG. 5 shows induction of Th1 cell apoptosis by Lactobacillus acidophilus L-92.
- FIG. 6 shows induction of apoptosis of T cells in spleen.
- FIG. 7 shows induction of apoptosis of T cells in mesenteric lymph nodes.
- the inducer of T cell apoptosis of the present invention comprises a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium as an active element. As described in Examples below, it was observed in a study where lactic acid bacterial cells are added to T cells derived from spleen cells of mice, showing that such a lactic acid bacterium has an activity of inducing T cell apoptosis.
- Examples of the lactic acid bacterium belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus amylovorus and kinds of stuff.
- Examples of the lactic acid bacterium belonging to the genus Bifidobacterium include Bifidobacterium catenulatum, Bifidobacterium longum and et alia.
- lactic acid bacterium belonging to Lactobacillus acidophilus to be used for the inducer of T cell apoptosis of the present invention a particularly preferred bacterium is Lactobacillus acidophilus L-92 (deposited on Mar. 4, 1994 under Accession No. FERM BP-4981 at International Patent Organism Depositary).
- Lactobacillus acidophilus L-92 has the following microbiological properties.
- lactic acid bacterium belonging to Lactobacillus to be used for the inducer of T cell apoptosis in the present invention another particularly preferred bacterium is Lactobacillus amylovorus CP1750 (FERM BP-10532).
- Lactobacillus amylovorus CP1750 FERM BP-10532
- Examples of the lactic acid bacterium belonging to the genus Bifidobacterium include Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531). These strains were isolated from human intestine and have the following assimilation property.
- T cell apoptosis failure of T cell apoptosis is largely involved in prophylaxis of a disease such as an autoimmune disease or a type I allergy.
- a disease such as an autoimmune disease or a type I allergy.
- mucosal T cells are resistant to apoptosis (Ina K. et al., J. Immunol. 163: 1081, 1999; Boirivant M. et al., Gastroenterology 116: 557, 1999).
- the inducer of T cell apoptosis of the present invention is considered to be useful for prevention and treatment of a disease such as an allergic disease including atopic dermatitis, Crohn's disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma, Sjogren's syndrome, vitiligo vulgaris, insulin-dependent diabetes mellitus, ankylosing spondylitis and Basedow's disease.
- a disease such as an allergic disease including atopic dermatitis, Crohn's disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma, Sjogren's syndrome, vitiligo vulgaris, insulin-dependent diabetes mellitus, ankylosing spondylitis and Basedow's disease.
- the lactic acid bacterium to be used as the inducer of T cell apoptosis of the present invention may be of any strain of the genus Lactobacillus or the genus Bifidobacterium .
- Any medium may be used for the culture of such a lactic acid bacterium, as long as it can support growth of the lactic acid bacterium, including, for example, media containing animal milk, skimmed milk, milk whey, MRS medium, GAM medium, BL medium, Briggs liver broth, a synthetic medium and kinds of stuff.
- the culture temperature is in the range from 25° C. to 50° C., preferably in the range from 35° C. to 42° C.
- the culture time is in the range from 3 hours to 48 hours, preferably in the range from 8 hours to 20 hours. Further, neutralization culture or filtration culture may be carried out using any of these media.
- the fermented lactic acid bacterial cells the fermented broth may be used as such, or only bacterial cells may be collected by centrifugation or filtration. Further, the bacterial cells can also be used in the form of lyophilized bacterial cells. Further, heat-treated bacterial cells, homogenized bacterial cells and kinds of stuff may also be used.
- a bacterial cell component is added to any of various food materials, such as drinks, tableted candies, paste, bread and confectionery products to provide a health drink, a health food or a functional food. Further, a medicine containing the bacterial cell component as an active ingredient may be provided.
- the inducer of T cell apoptosis of the present invention can be formulated into a pharmaceutical preparation by a method well known to those skilled in the state of art.
- lactic acid bacterial cells or a processed product thereof can be formulated into a preparation by appropriately combining it with a pharmaceutically acceptable carrier or medium, including sterile water, physiological saline, a plant oil, an emulsifying agent, a suspending agent, a surfactant, a stabilizer, a flavor, an excipient, a vehicle, a preservative, a binder, or the kinds of stuff, and mixing them into a unit dosage form required for generally accepted pharmaceutical practice.
- a pharmaceutically acceptable carrier or medium including sterile water, physiological saline, a plant oil, an emulsifying agent, a suspending agent, a surfactant, a stabilizer, a flavor, an excipient, a vehicle, a preservative, a binder, or the kinds of stuff, and mixing them into a unit
- lactic acid bacterial cells or a processed product thereof can be formulated as a tablet, a pill, a sugar-coated agent, a capsule, a liquid, a gel, a syrup, a slurry, a suspension, or the kind of stuff by mixing with a pharmaceutically acceptable carrier well known in the state of art.
- lactic acid bacterial cells or a processed product thereof can be formulated according to standard pharmaceutical practice by using a pharmaceutically acceptable vehicle well known in the state of art.
- Examples of an appropriate administration route for the inducer of T cell apoptosis of the present invention include, but not limited to, oral administration, intrarectal administration, transmucosal administration, intestinal administration, intramuscular injection, subcutaneous injection, intramedullary injection, intrathecal injection, direct intraventricular injection, intravenous injection, intravitreous injection, intraperitoneal injection, intranasal injection and intraocular injection.
- the administration route and method can be appropriately selected depending on the patient's age and their symptoms.
- the inducer of T cell apoptosis of the present invention is orally administered.
- the administration amount of the inducer of T cell apoptosis of the present invention will depend on the age, body weight, symptoms, therapeutic efficacy, administration method, treatment time or the other conditions, however, it is generally in the range of 1 mg to 1000 mg per dose per adult, and the dose can be orally administered once to several times a day. It should be noted that since the lactic acid bacterium, i.e. the active component is edible, there is no restriction on the administration amount from the view point of safety.
- Lactic acid bacteria belonging to the genus Lactobacillus and lactic acid bacteria belonging to the genus Bifidobacterium were cultured at 37° C. for 18 hours in MRS medium and GAM medium, respectively. After the culture, the lactic acid bacterial cells were collected by centrifugation, washed and lyophilized. The dried bacterial cells were suspended in a PBS solution, treated by heating at 100° C. for 10 minutes and used in the following experiments.
- TCR TCR-transgenic mouse bearing ⁇ -T cell receptor (TCR) gene derived from a T cell clone DO11.10 that I-A d restrictively recognizes a region between the 323rd and 339th residues of ovalbumin (hereinafter referred to as OVA), and a single cell suspension was prepared.
- CD4 microbeads (Militenyi Biotec) suspended in MACS buffer (PBS containing 0.5% bovine serum albumin and 2 mM EDTA) were reacted with the cell suspension at 4° C. for 15 minutes.
- CD4-positive T cells After the cells were washed, positive selection was collected using a magnetic separation column (Militenyi Biotec) to prepare CD4-positive T cells.
- the spleen was excised from a BALB/c mouse and a single cell suspension was prepared.
- Thy1.2 microbeads (Militenyi Biotec) suspended in MACS buffer were reacted with the cell suspension at 4° C. for 15 minutes. After the cells were washed, the negatively selected cell fraction was collected using a magnetic separation column, and used as antigen-presenting cells.
- the CD4-positive T cells derived from the spleen of a DO11.10 mouse and the antigen presenting cells derived from the spleen of a BALB/c mouse were prepared at 5 ⁇ 10 5 /ml and 1.5 ⁇ 10 6 /ml, respectively, and cultured in RPMI1640 medium (containing 100 units/ml penicillin, 100 ⁇ g/ml streptomycin, 5 ⁇ 10 ⁇ 5 M mercaptoethanol and 0.03% glutamine) containing 5% fetal bovine serum, and then stimulated with 1 mg/ml OVA (Seikagaku Corporation). Heat-killed lactic acid bacterial cells were added (10 ⁇ g/ml) and cultured at 37° C. under 5% carbon dioxide gas.
- Method of detecting apoptosis The cells cultured for 4 days were collected and reacted with anti-mouse CD16/32 (FC ⁇ III/II Receptor) antibody (FcBlockTM; BD Pharmingen) diluted with FACS buffer (PBS containing 1% fetal bovine serum and 0.1% sodium azide) at 4° C. for 10 minutes to avoid non-specific binding to Fc receptors, and then stained with FITC-labeled KJ1.26 (anti-chronotype antibody against DO11.10 T cell). Then, the cells were stained using Annexin V-PE Apoptosis Detection kit I (BD Pharmingen). The stained cells were detected using FACS LSR (BD) and the percentage of Annexin V-positive cells in KJ1.26-positive cells was determined.
- FACS buffer PBS containing 1% fetal bovine serum and 0.1% sodium azide
- test results are shown in FIG. 1 .
- An activity of inducing naive T cell apoptosis was observed in all the lactic acid bacteria tested. Further, an assay of cytokine in the culture supernatant showed that IL-2 production was decreased by the antigen stimulation (data not shown).
- Example 2 The preparation of cells and the detection of apoptosis were carried out in the same manner as in Example 2.
- the cells were cultured in accordance with Example 2, except that Lactobacillus acidophilus L-92 was used at concentrations of 0.1, 1.0 and 10 ⁇ g/ml as heat-killed lactic acid bacterial preparations.
- Th2 cells The CD4-positive T cells derived from the spleen of a DO11.10 mouse were prepared at 5 ⁇ 10 5 /ml, and the antigen-presenting cells derived from the spleen of a BALB/c mouse treated with 50 ⁇ g/ml mitomycin C (Sigma) at 37° C. for 30 minutes were prepared at 1.5 ⁇ 10 6 /ml. Then, 5 ⁇ g/ml anti-mouse IL-12 antibody (clone C17.8) and 2 ng/ml recombinant mouse IL-4 were added to the culture medium and the cells were cultured for 7 days in the presence of 1 mg/ml OVA. Then, the cells were collected and used as Th2 cells. The method of culturing cells and the method of detecting apoptosis are the same as those in Example 2.
- an anti-IL-4 antibody (clone: 11B11, BD Pharmingen) solution diluted to 1 ⁇ g/ml in 0.1 M Na 2 HPO 4 were added to an immunoplate (Nunc), and the plate was left overnight at 4° C., whereby the plate was coated with the antibody. After the wells were washed with PBS containing 0.05% Tween 20 (PBS-Tween), 100 ⁇ l of a 1% BSA/PBS-Tween solution was added and the plate was let stand at room temperature for 2 hours to block the plate.
- PBS-Tween PBS containing 0.05% Tween 20
- FIGS. 3 and 4 The test results are shown in FIGS. 3 and 4 .
- An activity of inducing apoptosis of Th2 cells was observed in all the lactic acid bacteria tested ( FIG. 3 ).
- the level of IL-4 produced by Th2 cells was decreased, demonstrating that Th2 cells were indeed decreased by apoptosis ( FIG. 4 ).
- Th1 cells The CD4-positive T cells derived from the spleen of a DO11.10 mice were prepared at 5 ⁇ 10 5 /ml, and the antigen presenting cells derived from the spleen of BALB/c mice treated with 50 ⁇ g/ml mitomycin C (Sigma) at 37° C. for 30 minutes were prepared at 1.5 ⁇ 10 6 /ml. Then, 5 ⁇ g/ml anti-mouse IL-4 antibody and 2 ng/ml recombinant mouse IL-12 were added to the culture medium and the cells were cultured for 7 days in the presence of 1 mg/ml OVA. Then, the cells were collected and used as Th1 cells. The method of culturing cells and the method of detecting apoptosis are the same as those in Example 2.
- the test results are shown in FIG. 5 .
- the strain L-92 was demonstrated to have an activity of inducing Th1 cell apoptosis.
- the results from Examples 2 to 5 suggested that the strain L-92 may suppress overexpression of activated T cells by inducing apoptosis in T cells stimulated by an antigen.
- mice with OVA-specific T cell receptors DO11.10 mice
- OVA Wired Chemical Industries Ltd., Cat. No. 012-09885
- aqueous solution was given as drinking water.
- the control group mice received normal CE-2 diet
- the L-92 group mice received CE-2 diet containing 0.05% heat-killed L-92 cells.
- the non-treated group (NT group) mice received normal water and normal CE-2 diet.
- OVA antigen-specific T cells Seven days later, the spleen and the mesenteric lymph nodes were excised, and the percentage of OVA antigen-specific T cells was determined by double staining with an FITC-labeled anti-CD4 antibody and a PE-labeled KJ1.26 antibody (OVA-TCR-specific antibody) using a flow cytometor.
- FIG. 6 spleen
- FIG. 7 mesenteric lymph nodes
- the inducer of T cell apoptosis according to the present invention is safe when orally taken for a long period of time, because it comprises a lactic acid bacterium. Further, it induces apoptosis of excess T cells, therefore it can be expected to prevent and/or cure an inflammatory disease caused by excess T cells, such as an organ-specific autoimmune disease or allergy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
Abstract
An inducer of T cell apoptosis and a health food for inducing T cell apoptosis comprising as an active ingredient of a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium are disclosed. Particularly preferred lactic acid bacteria belonging to the genus Lactobacillus or the genus Bifidobacterium are Lactobacillus acidophilus L-92 (FERM BP-4981), Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531). The inducer of T cell apoptosis of the invention is useful in the prevention and cure of a disease such as an organ-specific autoimmune disease or type I allergy.
Description
- The present invention relates to an inducer of apoptosis of T cells, which comprises a lactic acid bacterial cell as an active component.
- The mammalian immune system protects the host by recognizing bacteria, viruses and kinds of stuff as antigens and eliminating them through the action of the system. The immune system is roughly classified into cellular immunity and humoral immunity, and the both immune systems affect each other to optimize the immune reactions for host defense. T cells participate to play an important role in the modulation of the function of the immune system.
- T cells are broadly classified into Th1 and Th2 cells. Th1 cells enhance cellular immunity and Th2 cells enforce humoral immunity. The imbalance in the Th1/Th2 ratio may cause various immune diseases. It is considered that when Th1 cells are dominant, an organ-specific autoimmune disease occurs and when Th2 cells are dominant, a type I allergy or related diseases occur. Therefore, there has been a requirement for a food, a food additive and a medicine, which are useful for realizing the potential for maintaining the Th1/Th2 balance.
- References cited herein include Ina K. et al., J. Immunol. 163: 1081, 1999, Boirivant M. et al., Gastroenterology 116: 557, 1999, Watanabe-Fukunaga R. et al., Nature 356:314, 1992, Akdis M. et al., FASEB J. 17: 1026, 2003 and Guerra F. et al., J. Allergy Clin. Immunol. 107:647, 2001.
- An object of the present invention is to provide a novel and safe means for inducing apoptosis of excess T cells that may cause various diseases and to facilitate the prevention and cure of a disease such as an organ-specific autoimmune disease or a type I allergy.
- The present invention is based on a new finding that when bacterial cells of a specific type of lactic acid bacterial strain is introduced into a state of excess reactivity of T cells, apoptosis of T cells is induced.
- The present invention provides an inducer of T cell apoptosis comprising as an active ingredient a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium. Furthermore, the present invention provides a health food for inducing T cell apoptosis comprising a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium.
- In another aspect, the present invention provides novel lactic acid bacteria, i.e., Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531).
- The inducer of T cell apoptosis according to the present invention is safe even if it is orally taken for a long period of time, because of long experience of usage of lactic acid bacteria as starter cultures for fermentation foods such as yoghurt, pickles and the kind of stuff. In addition, it is expected that the inducer of the invention induces apoptosis of excess T cells to prevent and/or cure an inflammatory disease, such as an organ-specific autoimmune disease or an allergy caused by excess T cells.
-
FIG. 1 shows induction of naive T cell apoptosis by a variety of lactic acid bacteria. -
FIG. 2 shows a dose-dependent induction of T cell apoptosis by Lactobacillus acidophilus L-92. -
FIG. 3 shows induction of Th2 cell apoptosis by a variety of lactic acid bacteria. -
FIG. 4 shows level of IL-4 produced by Th2 cells treated with a variety of lactic acid bacteria. -
FIG. 5 shows induction of Th1 cell apoptosis by Lactobacillus acidophilus L-92. -
FIG. 6 shows induction of apoptosis of T cells in spleen. -
FIG. 7 shows induction of apoptosis of T cells in mesenteric lymph nodes. - The inducer of T cell apoptosis of the present invention comprises a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium as an active element. As described in Examples below, it was observed in a study where lactic acid bacterial cells are added to T cells derived from spleen cells of mice, showing that such a lactic acid bacterium has an activity of inducing T cell apoptosis.
- Examples of the lactic acid bacterium belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus amylovorus and kinds of stuff. Examples of the lactic acid bacterium belonging to the genus Bifidobacterium include Bifidobacterium catenulatum, Bifidobacterium longum and et alia.
- As the lactic acid bacterium belonging to Lactobacillus acidophilus to be used for the inducer of T cell apoptosis of the present invention, a particularly preferred bacterium is Lactobacillus acidophilus L-92 (deposited on Mar. 4, 1994 under Accession No. FERM BP-4981 at International Patent Organism Depositary).
- Lactobacillus acidophilus L-92 has the following microbiological properties.
- 4) Gram staining: Positive
- 2) Formation of indole: Negative,
3) Reduction of nitrate: Negative,
4) Attitude to oxygen: Facultative anaerobic, - 6) Formation of DL lactic acid from glucose by homolactic fermentation, Formation of gas: Non
7) Formation of acid from sugars: -
Glucose + Melibiose − Lactose + Raffinose + Mannose + Mannitol − Fructose + Sorbitol − Galactose + Esculin + Sucrose + Salicin + Arabinose − N-acetylglucosamin + Maltose + Amygdalin + Xylose − Gentiobiose + Rhamnose − Melezitose − Cellobiose + Dextrin − Trehalose + Starch − - In addition, as the lactic acid bacterium belonging to Lactobacillus to be used for the inducer of T cell apoptosis in the present invention, another particularly preferred bacterium is Lactobacillus amylovorus CP1750 (FERM BP-10532). Examples of the lactic acid bacterium belonging to the genus Bifidobacterium include Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531). These strains were isolated from human intestine and have the following assimilation property.
-
TABLE 1 Strain Lactobacillus Bifidobacterium Bifidobacterium amylovorus catenulatum CP2829 longum CP760 CP1750 Accession No. FERM FERM FERM BP-10533 BP-10531 BP-10532 1 Glycerol − − − 2 Erythritol − − − 3 D-arabinose − − − 4 L-arabinose + + − 5 Ribose + + − 6 D-xylose + + − 7 L-xylose − − − 8 Adonitol − − − 9 β-methyl-D-xyloside − − − 10 Galactose + + + 11 Glucose + + + 12 Fructose + + + 13 Mannose − + + 14 Sorbose − − − 15 Rhamnose − − − 16 Dulcitol − − − 17 Iinositol − − − 18 Mannitol + − − 19 Sorbitol + − − 20 α-methyl-D-mannoside − − − 21 α-methyl-D-glucoside − + − 22 N-acetylglucosamine − − + 23 Amygdalin + − − 24 Arbutin + − − 25 Esculin + − − 26 Salicin + − − 27 Cellobiose + + + 28 Maltose + + + 29 Lactose + + + 30 Melibiose + + − 31 Saccharose + + + 32 Trehalose + − − 33 Inulin − − − 34 Melezitose − + − 35 Raffinose + + + 36 Starch − − + 37 Glycogen − − − 38 Xylitol − − − 39 Gentiobiose + − + 40 D-turanose + + − 41 D-lyxose − − − 42 D-tagatose − − − 43 D-fucose − − − 44 L-fucose − − − 45 D-arabitol − − − 46 L-arabitol − − − 47 Gluconate + − − 48 2-keto-gluconate − − − 49 5-keto-gluconate − + − - It is known that failure of T cell apoptosis is largely involved in prophylaxis of a disease such as an autoimmune disease or a type I allergy. For example, in a patient with Crohn's disease, which is one of the organ-specific autoimmune diseases, mucosal T cells are resistant to apoptosis (Ina K. et al., J. Immunol. 163: 1081, 1999; Boirivant M. et al., Gastroenterology 116: 557, 1999). In an MRL-lpr/lpr mouse, auto-reactive T cells that should be eliminated by apoptosis under normal conditions are not eliminated and accumulated in the peripheral lymphoid tissues to cause an autoimmune reaction (Watanabe-Fukunaga R. et al., Nature 356:314, 1992). In patients with atopic dermatitis, Th1 cells tend to undergo apoptosis and Th2 cells proliferate (Akdis M. et al., FASEB J. 17: 1026, 2003), while in patients with atopic dermatitis receiving immunotherapy, Th2 cells tend to undergo apoptosis (Guerra F. et al., J. Allergy Clin. Immunol. 107:647, 2001). In other words, it is believed that a disease occurs when excess T cells cannot be eliminated by apoptosis, and the disease can be cured if appropriate apoptosis can be induced.
- Accordingly, the inducer of T cell apoptosis of the present invention is considered to be useful for prevention and treatment of a disease such as an allergic disease including atopic dermatitis, Crohn's disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma, Sjogren's syndrome, vitiligo vulgaris, insulin-dependent diabetes mellitus, ankylosing spondylitis and Basedow's disease.
- The lactic acid bacterium to be used as the inducer of T cell apoptosis of the present invention may be of any strain of the genus Lactobacillus or the genus Bifidobacterium. Any medium may be used for the culture of such a lactic acid bacterium, as long as it can support growth of the lactic acid bacterium, including, for example, media containing animal milk, skimmed milk, milk whey, MRS medium, GAM medium, BL medium, Briggs liver broth, a synthetic medium and kinds of stuff. The culture temperature is in the range from 25° C. to 50° C., preferably in the range from 35° C. to 42° C. The culture time is in the range from 3 hours to 48 hours, preferably in the range from 8 hours to 20 hours. Further, neutralization culture or filtration culture may be carried out using any of these media. In addition, as for the fermented lactic acid bacterial cells, the fermented broth may be used as such, or only bacterial cells may be collected by centrifugation or filtration. Further, the bacterial cells can also be used in the form of lyophilized bacterial cells. Further, heat-treated bacterial cells, homogenized bacterial cells and kinds of stuff may also be used. A bacterial cell component is added to any of various food materials, such as drinks, tableted candies, paste, bread and confectionery products to provide a health drink, a health food or a functional food. Further, a medicine containing the bacterial cell component as an active ingredient may be provided.
- The inducer of T cell apoptosis of the present invention can be formulated into a pharmaceutical preparation by a method well known to those skilled in the state of art. For example, lactic acid bacterial cells or a processed product thereof can be formulated into a preparation by appropriately combining it with a pharmaceutically acceptable carrier or medium, including sterile water, physiological saline, a plant oil, an emulsifying agent, a suspending agent, a surfactant, a stabilizer, a flavor, an excipient, a vehicle, a preservative, a binder, or the kinds of stuff, and mixing them into a unit dosage form required for generally accepted pharmaceutical practice.
- For oral administration, lactic acid bacterial cells or a processed product thereof can be formulated as a tablet, a pill, a sugar-coated agent, a capsule, a liquid, a gel, a syrup, a slurry, a suspension, or the kind of stuff by mixing with a pharmaceutically acceptable carrier well known in the state of art. For parenteral administration, lactic acid bacterial cells or a processed product thereof can be formulated according to standard pharmaceutical practice by using a pharmaceutically acceptable vehicle well known in the state of art.
- Examples of an appropriate administration route for the inducer of T cell apoptosis of the present invention include, but not limited to, oral administration, intrarectal administration, transmucosal administration, intestinal administration, intramuscular injection, subcutaneous injection, intramedullary injection, intrathecal injection, direct intraventricular injection, intravenous injection, intravitreous injection, intraperitoneal injection, intranasal injection and intraocular injection. The administration route and method can be appropriately selected depending on the patient's age and their symptoms. Preferably, the inducer of T cell apoptosis of the present invention is orally administered. The administration amount of the inducer of T cell apoptosis of the present invention will depend on the age, body weight, symptoms, therapeutic efficacy, administration method, treatment time or the other conditions, however, it is generally in the range of 1 mg to 1000 mg per dose per adult, and the dose can be orally administered once to several times a day. It should be noted that since the lactic acid bacterium, i.e. the active component is edible, there is no restriction on the administration amount from the view point of safety.
- Hereinafter, the present invention is described in more detail with reference to Examples, however, the present invention is not limited to these Examples.
- The disclosure of all patents and documents cited herein are entirely incorporated herein as reference. The present application claims priority based on the Japanese Patent Application Nos. 2005-60285 and 2005-86546, the disclosure of which is entirely incorporated herein as reference.
- The following examples further illustrate the present invention. The examples below are not limiting and are merely representative of various aspects and features of the present invention.
- Lactic acid bacteria belonging to the genus Lactobacillus and lactic acid bacteria belonging to the genus Bifidobacterium were cultured at 37° C. for 18 hours in MRS medium and GAM medium, respectively. After the culture, the lactic acid bacterial cells were collected by centrifugation, washed and lyophilized. The dried bacterial cells were suspended in a PBS solution, treated by heating at 100° C. for 10 minutes and used in the following experiments.
- Preparation of cells: The spleen was excised from a DO11.10 TCR-transgenic mouse bearing αβ-T cell receptor (TCR) gene derived from a T cell clone DO11.10 that I-Ad restrictively recognizes a region between the 323rd and 339th residues of ovalbumin (hereinafter referred to as OVA), and a single cell suspension was prepared. CD4 microbeads (Militenyi Biotec) suspended in MACS buffer (PBS containing 0.5% bovine serum albumin and 2 mM EDTA) were reacted with the cell suspension at 4° C. for 15 minutes. After the cells were washed, positive selection was collected using a magnetic separation column (Militenyi Biotec) to prepare CD4-positive T cells. The spleen was excised from a BALB/c mouse and a single cell suspension was prepared. Thy1.2 microbeads (Militenyi Biotec) suspended in MACS buffer were reacted with the cell suspension at 4° C. for 15 minutes. After the cells were washed, the negatively selected cell fraction was collected using a magnetic separation column, and used as antigen-presenting cells.
- Culture of cells: The CD4-positive T cells derived from the spleen of a DO11.10 mouse and the antigen presenting cells derived from the spleen of a BALB/c mouse were prepared at 5×105/ml and 1.5×106/ml, respectively, and cultured in RPMI1640 medium (containing 100 units/ml penicillin, 100 μg/ml streptomycin, 5×10−5 M mercaptoethanol and 0.03% glutamine) containing 5% fetal bovine serum, and then stimulated with 1 mg/ml OVA (Seikagaku Corporation). Heat-killed lactic acid bacterial cells were added (10 μg/ml) and cultured at 37° C. under 5% carbon dioxide gas.
- Method of detecting apoptosis: The cells cultured for 4 days were collected and reacted with anti-mouse CD16/32 (FCγIII/II Receptor) antibody (FcBlock™; BD Pharmingen) diluted with FACS buffer (PBS containing 1% fetal bovine serum and 0.1% sodium azide) at 4° C. for 10 minutes to avoid non-specific binding to Fc receptors, and then stained with FITC-labeled KJ1.26 (anti-chronotype antibody against DO11.10 T cell). Then, the cells were stained using Annexin V-PE Apoptosis Detection kit I (BD Pharmingen). The stained cells were detected using FACS LSR (BD) and the percentage of Annexin V-positive cells in KJ1.26-positive cells was determined.
- The test results are shown in
FIG. 1 . An activity of inducing naive T cell apoptosis was observed in all the lactic acid bacteria tested. Further, an assay of cytokine in the culture supernatant showed that IL-2 production was decreased by the antigen stimulation (data not shown). - The preparation of cells and the detection of apoptosis were carried out in the same manner as in Example 2. The cells were cultured in accordance with Example 2, except that Lactobacillus acidophilus L-92 was used at concentrations of 0.1, 1.0 and 10 μg/ml as heat-killed lactic acid bacterial preparations.
- The test results are shown in
FIG. 2 . It was observed that Lactobacillus acidophilus L-92 induces T cell apoptosis in a dose-dependent manner. - Preparation of Th2 cells: The CD4-positive T cells derived from the spleen of a DO11.10 mouse were prepared at 5×105/ml, and the antigen-presenting cells derived from the spleen of a BALB/c mouse treated with 50 μg/ml mitomycin C (Sigma) at 37° C. for 30 minutes were prepared at 1.5×106/ml. Then, 5 μg/ml anti-mouse IL-12 antibody (clone C17.8) and 2 ng/ml recombinant mouse IL-4 were added to the culture medium and the cells were cultured for 7 days in the presence of 1 mg/ml OVA. Then, the cells were collected and used as Th2 cells. The method of culturing cells and the method of detecting apoptosis are the same as those in Example 2.
- Fifty microliters of an anti-IL-4 antibody (clone: 11B11, BD Pharmingen) solution diluted to 1 μg/ml in 0.1 M Na2HPO4 were added to an immunoplate (Nunc), and the plate was left overnight at 4° C., whereby the plate was coated with the antibody. After the wells were washed with PBS containing 0.05% Tween 20 (PBS-Tween), 100 μl of a 1% BSA/PBS-Tween solution was added and the plate was let stand at room temperature for 2 hours to block the plate. After the wells were washed with PBS-Tween, then after, 50 μl of a standard specimen in a serial dilution or each culture supernatant diluted in a 1% BSA/PBS-Tween solution was added to the well, and the plate was kept at room temperature for 2 hours. After the wells were washed with PBS-Tween, 50 μl of a biotinylated anti-IL-4 antibody (clone: BVD4-1D11, BD Pharmingen) diluted to 0.25 μg/ml in a 1% BSA/PBS-Tween solution was added and the plate was stood at room temperature for 2 hours. After the wells were washed with PBS-Tween, 50 μl of an alkaline phosphatase streptavidin (Zymed) solution diluted to 1.5 μg/ml in a 1% BSA/PBS-Tween solution was added and the plate was let stand at room temperature for 1 hour. After the wells were washed with PBS-Tween, 50 μl of 4-nitrophenyl disodium phosphate (Tokyo Kasei Kogyo Co., Ltd.) dissolved in diethanolamine-hydrochloride buffer (pH 8.9) at 1 mg/ml was added and the absorbance at 405 nm was measured.
- The test results are shown in
FIGS. 3 and 4 . An activity of inducing apoptosis of Th2 cells was observed in all the lactic acid bacteria tested (FIG. 3 ). Furthermore, the level of IL-4 produced by Th2 cells was decreased, demonstrating that Th2 cells were indeed decreased by apoptosis (FIG. 4 ). - Induction of Th1 cells: The CD4-positive T cells derived from the spleen of a DO11.10 mice were prepared at 5×105/ml, and the antigen presenting cells derived from the spleen of BALB/c mice treated with 50 μg/ml mitomycin C (Sigma) at 37° C. for 30 minutes were prepared at 1.5×106/ml. Then, 5 μg/ml anti-mouse IL-4 antibody and 2 ng/ml recombinant mouse IL-12 were added to the culture medium and the cells were cultured for 7 days in the presence of 1 mg/ml OVA. Then, the cells were collected and used as Th1 cells. The method of culturing cells and the method of detecting apoptosis are the same as those in Example 2.
- The test results are shown in
FIG. 5 . The strain L-92 was demonstrated to have an activity of inducing Th1 cell apoptosis. The results from Examples 2 to 5 suggested that the strain L-92 may suppress overexpression of activated T cells by inducing apoptosis in T cells stimulated by an antigen. - To transgenic mice with OVA-specific T cell receptors (DO11.10 mice), 2% OVA (Wako Pure Chemical Industries Ltd., Cat. No. 012-09885) aqueous solution was given as drinking water. The control group mice received normal CE-2 diet, and the L-92 group mice received CE-2 diet containing 0.05% heat-killed L-92 cells. Also the non-treated group (NT group) mice received normal water and normal CE-2 diet. Seven days later, the spleen and the mesenteric lymph nodes were excised, and the percentage of OVA antigen-specific T cells was determined by double staining with an FITC-labeled anti-CD4 antibody and a PE-labeled KJ1.26 antibody (OVA-TCR-specific antibody) using a flow cytometor.
- The test results are shown in
FIG. 6 (spleen) andFIG. 7 (mesenteric lymph nodes). A decrease in antigen-specific T cells was also observed in these tissues of the animals, demonstrating that the strain L-92 has some effect on the immune system and induces apoptosis in antigen-specific T-cells even when orally administrated. - The inducer of T cell apoptosis according to the present invention is safe when orally taken for a long period of time, because it comprises a lactic acid bacterium. Further, it induces apoptosis of excess T cells, therefore it can be expected to prevent and/or cure an inflammatory disease caused by excess T cells, such as an organ-specific autoimmune disease or allergy.
Claims (9)
1. An inducer of T cell apoptosis comprising as an active ingredient a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium.
2. The inducer of T cell apoptosis according to claim 1 , wherein the lactic acid bacterium belonging to the genus Lactobacillus is a lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus and Lactobacillus amylovorus.
3. The inducer of T cell apoptosis according to claim 1 , wherein the lactic acid bacterium belonging to the genus Bifidobacterium is a lactic acid bacterium selected from the group consisting of Bifidobacterium catenulatum and Bifidobacterium longum.
4. The inducer of T cell apoptosis according to claim 1 , wherein the lactic acid bacterium is a lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus L-92 (FERM BP-4981), Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531).
5. A health food for inducing T cell apoptosis comprising a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium.
6. The health food for inducing T cell apoptosis according to claim 5 , wherein the lactic acid bacterium is a lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus L-92 (FERM BP-4981), Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531).
7. A novel lactic acid bacterium, Lactobacillus amylovorus CP1750 (FERM BP-10532).
8. A novel lactic acid bacterium, Bifidobacterium catenulatum CP2829 (FERM BP-10533).
9. A novel lactic acid bacterium, Bifidobacterium longum CP760 (FERM BP-10531).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005060285 | 2005-03-04 | ||
JP2005-060285 | 2005-03-04 | ||
JP2005-086546 | 2005-03-24 | ||
JP2005086546 | 2005-03-24 | ||
PCT/JP2006/304243 WO2006093313A1 (en) | 2005-03-04 | 2006-03-06 | T cell apoptosis inducer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/304243 A-371-Of-International WO2006093313A1 (en) | 2005-03-04 | 2006-03-06 | T cell apoptosis inducer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/167,483 Continuation US9339055B2 (en) | 2005-03-04 | 2011-06-23 | T cell apoptosis inducer and method therefore |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080166787A1 true US20080166787A1 (en) | 2008-07-10 |
Family
ID=36941341
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/883,377 Abandoned US20080166787A1 (en) | 2005-03-04 | 2006-03-06 | T Cell Apoptosis Inducer |
US13/167,483 Active 2029-06-04 US9339055B2 (en) | 2005-03-04 | 2011-06-23 | T cell apoptosis inducer and method therefore |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/167,483 Active 2029-06-04 US9339055B2 (en) | 2005-03-04 | 2011-06-23 | T cell apoptosis inducer and method therefore |
Country Status (5)
Country | Link |
---|---|
US (2) | US20080166787A1 (en) |
EP (2) | EP1854468B1 (en) |
JP (1) | JP5069556B2 (en) |
TW (1) | TW200700074A (en) |
WO (1) | WO2006093313A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247575A1 (en) * | 2006-12-21 | 2010-09-30 | Calpis Co., Ltd. | Agents for promoting iga production |
US9339055B2 (en) | 2005-03-04 | 2016-05-17 | Asahi Group Holdings, Ltd. | T cell apoptosis inducer and method therefore |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2442230A (en) * | 2006-09-29 | 2008-04-02 | Secretary Trade Ind Brit | Method of separating carbon nanotubes |
TWI356680B (en) * | 2007-01-05 | 2012-01-21 | Promd Biotech Co Ltd | Anti-allergy lactic acid bacteria |
JP2008195673A (en) * | 2007-02-14 | 2008-08-28 | Nippon Meat Packers Inc | Life-prolonging effect substances, infection-protecting effect / vaccine effect promoting substances, constructs for assaying the substances, and uses thereof |
ES2664724T3 (en) * | 2009-08-18 | 2018-04-23 | Nestec S.A. | Nutritional composition comprising strains of Bifidobacterium longum and reducing symptoms of food allergy, especially in infants and children |
JP5737646B2 (en) * | 2010-03-24 | 2015-06-17 | 森下仁丹株式会社 | Antiallergic agent |
FR2962134B1 (en) * | 2010-07-05 | 2014-12-19 | Bifinove | PROCESS FOR THE PREPARATION OF NON-SEPARATED MACROMOLECULAR COMPLEX (TOTUM) AND USES THEREOF IN THE PREVENTION OF ARTHRITIS DISORDERS |
JP5840368B2 (en) | 2011-02-02 | 2016-01-06 | カルピス株式会社 | Substances for preventing and improving arthritis |
US9173910B2 (en) | 2012-02-29 | 2015-11-03 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
EP3212001A4 (en) | 2014-10-31 | 2018-04-25 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
JP2020532515A (en) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | Methods and compositions for the treatment of microbiome-related disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707854A (en) * | 1994-03-11 | 1998-01-13 | Calpis Food Industry Co., Ltd. | Lactic acid bacteria of the Genus lactobacillus |
US20030215429A1 (en) * | 1998-02-20 | 2003-11-20 | Mendes S.R.L. | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
US20040009490A1 (en) * | 1999-08-09 | 2004-01-15 | Genesis Research And Development Corp. Ltd. | Polynucleotides, materials incorporating them, and methods for using them |
US20050214270A1 (en) * | 2002-06-26 | 2005-09-29 | Naouki Yamamoto | Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265064A (en) * | 1993-11-23 | 1995-10-17 | Taketoshi Yamada | Composition for improving enterobacterial flora |
JP3400282B2 (en) * | 1997-02-21 | 2003-04-28 | 株式会社ヤクルト本社 | Lipid metabolism improver and food containing it |
JPH10309178A (en) * | 1997-05-09 | 1998-11-24 | Wakamoto Pharmaceut Co Ltd | Antiallergic agent and fermented food containing Bifidobacterium as active ingredient |
JP2002306125A (en) * | 2001-04-12 | 2002-10-22 | Morinaga Milk Ind Co Ltd | Nutritional composition for infants in packaging containing probiotics |
PE20030284A1 (en) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | BIFIDOBACTERIUM STRAINS |
CA2364249A1 (en) | 2001-11-27 | 2003-05-27 | Unknown-Inconnu | Effect of lactic bacteria on tumour cell death |
TWI241912B (en) * | 2002-10-30 | 2005-10-21 | Food Industry Res & Dev Inst | Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol |
US20040208863A1 (en) | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
WO2004076615A2 (en) | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
JP4479162B2 (en) * | 2003-03-18 | 2010-06-09 | 高梨乳業株式会社 | Immune function regulator and immune function-modulating food |
JP2005060285A (en) | 2003-08-11 | 2005-03-10 | Masako Ito | Method for wipe-cleaning oral cavity |
JP3862687B2 (en) | 2003-09-09 | 2006-12-27 | 沖電気工業株式会社 | Level shifter circuit |
TW200637908A (en) | 2005-01-04 | 2006-11-01 | Calpis Co Ltd | Method for preparation of lactic acid bacterium having anti-allergic activity |
TW200700074A (en) | 2005-03-04 | 2007-01-01 | Calpis Co Ltd | Inducer of t cell apoptosis |
-
2006
- 2006-03-03 TW TW095107321A patent/TW200700074A/en unknown
- 2006-03-06 EP EP06728662.5A patent/EP1854468B1/en not_active Not-in-force
- 2006-03-06 US US11/883,377 patent/US20080166787A1/en not_active Abandoned
- 2006-03-06 JP JP2007506047A patent/JP5069556B2/en active Active
- 2006-03-06 WO PCT/JP2006/304243 patent/WO2006093313A1/en active Application Filing
- 2006-03-06 EP EP13154417.3A patent/EP2591790A1/en not_active Withdrawn
-
2011
- 2011-06-23 US US13/167,483 patent/US9339055B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707854A (en) * | 1994-03-11 | 1998-01-13 | Calpis Food Industry Co., Ltd. | Lactic acid bacteria of the Genus lactobacillus |
US20030215429A1 (en) * | 1998-02-20 | 2003-11-20 | Mendes S.R.L. | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
US20040009490A1 (en) * | 1999-08-09 | 2004-01-15 | Genesis Research And Development Corp. Ltd. | Polynucleotides, materials incorporating them, and methods for using them |
US20050214270A1 (en) * | 2002-06-26 | 2005-09-29 | Naouki Yamamoto | Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9339055B2 (en) | 2005-03-04 | 2016-05-17 | Asahi Group Holdings, Ltd. | T cell apoptosis inducer and method therefore |
US20100247575A1 (en) * | 2006-12-21 | 2010-09-30 | Calpis Co., Ltd. | Agents for promoting iga production |
US8226937B2 (en) | 2006-12-21 | 2012-07-24 | Calpis Co., Ltd. | Agents for promoting IgA production |
Also Published As
Publication number | Publication date |
---|---|
EP2591790A1 (en) | 2013-05-15 |
WO2006093313A1 (en) | 2006-09-08 |
EP1854468B1 (en) | 2013-04-24 |
JP5069556B2 (en) | 2012-11-07 |
EP1854468A1 (en) | 2007-11-14 |
EP1854468A4 (en) | 2012-02-08 |
US20110250189A1 (en) | 2011-10-13 |
TW200700074A (en) | 2007-01-01 |
JPWO2006093313A1 (en) | 2008-08-07 |
US9339055B2 (en) | 2016-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9339055B2 (en) | T cell apoptosis inducer and method therefore | |
US20230355690A1 (en) | Method of treatment with lactic acid bacteria | |
Sashihara et al. | An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases | |
US10405569B2 (en) | Lanctobacillus plantarum HAC01 strain having anti-inflammatory efficacy and metabolic disease alleviating efficacy and use thereof | |
US20200009202A1 (en) | Bacterial composition and its use | |
US7241441B2 (en) | Microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities | |
US20110081328A1 (en) | Use of selected lactic acid bacteria for reducing atherosclerosis | |
JP2005508617A (en) | Probiotic Bifidobacterium strains | |
JP2002534113A (en) | Bifidobacterium in the treatment of inflammatory diseases | |
US11026983B2 (en) | Bifidobacterium breve CBT BR3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same | |
Sashihara et al. | Effect of growth conditions of Lactobacillus gasseri OLL2809 on the immunostimulatory activity for production of interleukin-12 (p70) by murine splenocytes | |
KR102606079B1 (en) | Novel Ligilactobacillus animalis VA105 having immune-enhancing activity and use thereof | |
US20160279181A1 (en) | Intestinal barrier function enhancer containing lactic acid bacteria | |
RU2302458C2 (en) | Lactobacillus salivarius probiotic strain (variants), probiotic preparation based on the same, and method for treatment or prevention using lactobacillus salivarius strains | |
AU2007335423B2 (en) | IgA production promoter | |
KR100503570B1 (en) | Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities | |
KR102146706B1 (en) | Composition for improving allergic rhinitis containing fermented red ginseng concentrate having increased content of ginsenoside Rd using fermentation by Bifidobacterium animalis ssp. lactis HY8002 and Bifidobacterium adolescentis HY8502 mixture as effective component | |
EP1835021A1 (en) | Novel strain conferring anti-disease properties to host and bacterial cell composition | |
EP3578637A1 (en) | Novel lactic acid bacteria and use thereof | |
US20210393773A1 (en) | Compositions comprising bacterial strains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CALPIS CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJIWARA, SHIGERU;KANZATO, HIROKI;HACHIMURA, SATOSHI;REEL/FRAME:020191/0304;SIGNING DATES FROM 20070911 TO 20070914 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |